Tebentafusp (Kimmtrak)

From HemOnc.org - A Hematology Oncology Wiki
(Redirected from Tebentafusp (IMCgp100))
Jump to navigation Jump to search

Mechanism of action

Bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells.

Diseases for which it is used

  1. IMCgp100-202: Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Joshua AM, Sacco JJ, Shoushtari AN, Orloff M, Piulats JM, Milhem M, Salama AKS, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal RD, Hamid O, Abdullah SE, Holland C, Goodall H, Piperno-Neumann S; IMCgp100-202 Investigators. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 Sep 23;385(13):1196-1206. link to original article PubMed NCT03070392

Also known as

  • Code name: IMCgp100
  • Generic name: tebentafusp-tebn
  • Brand name: Kimmtrak